Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMe for recurrence prevention in primary liver cancer
NCT03178929Unknown
- Sponsor
- Beijing Insight Science & Technology
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of S-adenosylmethionine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing Insight Science & Technology. Primary endpoint: Time to tumor recurrence at 2 years. Status: unknown.
02
Drugs
S-adenosylmethionine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03178929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178929.